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Lung function abnormalities both at rest and during exercise are frequently observed in patients with chronic heart failure, also
in the absence of respiratory disease. Alterations of respiratory mechanics and of gas exchange capacity are strictly related to heart
failure. Severe heart failure patients often show a restrictive respiratory pattern, secondary to heart enlargement and increased lung
fluids, and impairment of alveolar-capillary gas diﬀusion, mainly due to an increased resistance to molecular diﬀusion across the
alveolar capillary membrane. Reduced gas diﬀusion contributes to exercise intolerance and to a worse prognosis. Cardiopulmonary
exercise test is considered the “gold standard” when studying the cardiovascular, pulmonary, and metabolic adaptations to exercise
in cardiac patients. During exercise, hyperventilation and consequent reduction of ventilation eﬃciency are often observed in heart
failure patients, resulting in an increased slope of ventilation/carbon dioxide (VE/VCO2) relationship. Ventilatory eﬃciency is as
strong prognostic and an important stratification marker. This paper describes the pulmonary abnormalities at rest and during
exercise in the patients with heart failure, highlighting the principal diagnostic tools for evaluation of lungs function, the possible
pharmacological interventions, and the parameters that could be useful in prognostic assessment of heart failure patients.
1. Introduction
Not only heart is involved in chronic heart failure but also
lung, kidney, peripheral and respiratory muscles, chemo-
ergoreceptors, neurohormonal mechanisms, mitochondria,
all play a major role in determining the complex clinical
syndrome of chronic heart failure. Indeed, energy deficit is
a relevant contributor to the development of cardiac and
skeletal myopathy. In heart failure several functions of muscle
bioenergetics are altered such as oxygen availability, sub-
strate oxidation, ATP production by the mitochondria, and
transfer to contractile apparatus [1]. Notably, the clinical
syndrome of heart failure is characterized by symptoms
apparently unrelated or partially related to the heart, such as
fatigue, dyspnea, anxiety, and exercise intolerance.
Dyspnea, either at rest or during exercise, is one of the
main symptoms in heart failure. Indeed, the most often used
heart failure grading methodology, the NYHA classification,
is based on dyspnea. Dyspnea is the result of a neurolog-
ical reconstruction of an abnormal physiological condition
characterized by hyperventilation and by high ventilation to
metabolic demand ratio. This leads to a reduced ventilatory
eﬃciency, which is physiologically defined as the amount of
ventilation needed to eliminate a given amount of CO2. The
excess of ventilation is due to an increase of dead space/tidal
volume (VD/VT) ventilation and of ventilatory drive from
peripheral chemo- and ergoreceptors. The reduced ventila-
tory eﬃciency during exercise is used more and more as a
prognostic marker in heart failure. In addition, an improve-
ment of the eﬃciency of ventilation is among the goals
2 Pulmonary Medicine
0
0
0
0
0 0
0
0
0
120
100
80
60
40
20
0
FVC FEVI DLCO 
VO2 max < 12 mL/Kg/min
VO2 max > 20 mL/Kg/minVO2 max 12–16 mL/Kg/min
VO2 max 16–20 mL/Kg/min
P
re
di
ct
ed
 v
al
u
e 
(%
)
Figure 1: Lung function at rest in 190 heart failure patients in stable clinical condition. Patients were grouped according to exercise capacity.
From left to right: peak VO2 < 12 mL/min/kg (black bars), peak VO2 = 12–16 mL/min/kg (white bars), peak VO2 = 16–20 mL/min/kg (grey
bars), and peak VO2 > 20 mL/min/kg (dashed bars). FVC: forced vital capacity; FEV1: forced expiratory volume 1 second; DLCO: lung
diﬀusion for carbon monoxide. Data from [8, Table 1].
of heart failure therapy. The following review will examine
the role of diﬀerent mechanisms underlying ventilatory eﬃ-
ciency evaluated with spirometry, lung gas diﬀusion meas-
urement, and cardiopulmonary exercise test in heart failure
patients.
2. Lung Abnormalities at Rest
Pulmonary abnormalities are part of the heart failure
syndrome, as both lung mechanics and alveolar-capillary gas
exchange are impaired [2–5]. In heart failure, pulmonary
abnormalities may be due to respiratory comorbidities but
also to heart failure itself. Therefore, standard spirometry
and resting lung diﬀusion for carbon monoxide (DLCO) [6]
provide an integrated evaluation of the respiratory function
and should be performed in all heart failure patients.
Moreover, it may be useful to split DLCO into its two sub-
components either using the classic Roughton and Forster
method or nitric oxide lung diﬀusion. Accordingly, Dm, the
resistance to molecular diﬀusion of carbon monoxide across
the alveolar-capillary membrane, and Vcap, the resistance
to carbon monoxide binding to hemoglobin, the so-called
pulmonary capillary blood volume, can be calculated [7].
2.1. Spirometry. Spirometry is the preliminary pulmonary
function test to assess respiratory mechanics.
Wasserman et al. [5] showed in a large multicenter study
that, at rest, forced expiratory volume in the first second and
vital capacity are either normal or proportionately reduced in
heart failure. More recently, Agostoni et al. [8] demonstrated
that pulmonary function at rest is usually normal in patients
with moderate heart failure, while a restrictive lung disease
is observed in 50% of patients with severe heart failure
(Figure 1). Cardiac enlargement in heart failure appears to
be involved in causing restrictive lung pattern [4, 9]. Indeed,
a negative correlation between cardiac size, as analyzed by
the cardiothoracic index at chest X-ray, and lung function
parameters, including alveolar volume, has been described
[4]. Notably, Palermo et al. [10] showed that, in heart failure,
pulmonary function varies in relationship with the position
of the body, being worst in the lateral decubitus. The larger
the heart, the greater the diﬀerence in lung function between
the sitting position and the lateral decubitus. Moreover,
McCormack [11] showed that the restrictive lung disease
secondary to severe heart failure seems to be completely
reversible after cardiac transplantation, with an increase in
forced vital capacity after transplantation, directly correlated
with the decrease in cardiac volume.
2.2. Lung Diﬀusion. Alterations of respiratory mechanics and
of gas exchange capacity are strictly related in heart failure
patients. Reduction in the pulmonary DLCO is well docu-
mented in heart failure [3, 13–15]. The acute pathogenetic
mechanisms of lung diﬀusion abnormalities in heart failure
are related to interstitial edema, alveolar-capillary membrane
hydrostatic injury, and altered alveolar fluid clearance. These
mechanisms result in a remodeling process that causes a
persistent reduction in alveolar-capillary membrane conduc-
tance and lung diﬀusion capacity. Indeed, Mettauer et al.
[16] demonstrated that DLCO is only partially restored after
cardiac transplantation. DLCO improves less in patients with
long standing heart failure. This implies that in heart failure
the alveolar-capillary membrane undergoes changes that are
only partially reversible with heart failure treatment [17].
Reduced Dm is the main component of impaired pul-
monary gas transfer in heart failure [18]. Puri et al. [18]
demonstrated that Dm decreases and Vcap increases in rela-
tionship with the severity of the disease. The Vcap increase
was interpreted as a compensatory mechanism aimed, by
pulmonary vessel recruitment, at preserving alveolar-
capillary diﬀusion. Vcap tends to increase in patients with
stable heart failure, but could decrease in the advanced
stages [19]. Agostoni et al. [8] showed that in severe heart
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failure in stable clinical condition there are few alveolar-
capillary units at work (low alveolar volume), characterized
by greater eﬃciency (high Dm/Vcap ratio) compared to
alveolar-capillary units in intermediate chronic heart failure
severity. However, the physiological mechanism behind this
phenomenon is still undefined. Indeed, Vcap is related to the
amount of hemoglobin participating in gas exchange, which,
on its turn, depends from hemoconcentration, cardiac
output, and the amount of capillary vessels in the ventilated
airways. The latter is related to pulmonary venous pressure.
In heart failure, the alveolar-capillary membrane sur-
face area available for gas exchange is reduced and par-
tially responsible for low Dm. Furthermore, Dm reduction
remains even after correction for alveolar volume (Dm/VA)
[18]. In fact, Dm is aﬀected by several factors including
interstitial edema that increases the distance between alveolar
gas and red blood cells, fibrosis, inability to further activate
the pump mechanism at the alveolar surface which enhances
chlorine and sodium transport [20], and peribronchial
edema that may reduce ventilation to some lung units. More-
over, there is a strict correlation between hemodynamics and
Dm, as proven by the observation that Dm decreases after
infusion of a small amount of saline (150 mL) [21] or after
exercise [22, 23].
Nevertheless, we must underline that, albeit several heart
failure models have been prepared to study the correlation
between increased congestion of lung interstitial space and
pulmonary function, a reliable model of lung function
abnormalities mimicking those present in heart failure does
not exist. Studies in healthy humans [24–26] demonstrated
a reduced vital capacity, forced expiratory volume, and total
lung capacity with a preserved DLCO after a rapid increase
fluid content. This observation is consistent with some
clinical findings. For instance, ultrafiltration, which acutely
reduces the congestion of lung interstitium, improves lung
mechanics but not DLCO in heart failure [17, 27].
DLCO is a limiting factor for exercise performance [28,
29], which improves (below sea level, as in the Dead Sea) or
worsens at diﬀerent altitudes more in heart failure patients
with reduced DLCO compared to subjects with a normal
DLCO [30, 31]. DLCO and Dm abnormalities have a relevant
prognostic capacity in heart failure [32], although we do not
know whether an improvement of DLCO with treatment is
associated with an improvement of prognosis.
More recently, a new biomarker of alveolar-capillary
membrane damage has been described [33, 34]. Increased
circulating plasma levels of surfactant protein B have been
reported in heart failure patients with a good correlation with
heart failure severity. The mature form of surfactant protein
B plays a crucial role in the formation and stabilization of
pulmonary surfactant film. The level of surfactant protein B
correlates with lung diﬀusion as well as peak VO2 and ven-
tilation versus CO2 production (VE/VCO2) slope [34]. The
clinical applicability of this biomarker is unclear at present.
3. Lung Abnormalities during Exercise
Cardiopulmonary exercise test (CPET) with incremental
increases in workload is considered as the “gold standard”
when studying the cardiovascular, pulmonary, and metabolic
adaptations to exercise in cardiac patients.
Traditionally, ventilatory limitation to exercise is assessed
by measuring the breathing reserve calculated as the diﬀer-
ence between minute ventilation at peak exercise and max-
imal voluntary ventilation or some estimate of the maximal
voluntary ventilation (typically the forced expiratory volume
in the first second multiplied by 35 or 40). Any diﬀerence
>15 L/min or breathing reserve >20–40% is interpreted as
consistent with exercise not being limited by ventilation
[35]. In normal individuals, there is a progressive increase
of ventilation (VE) during exercise, due to both VT and
respiratory rate increase. The increase in VT mainly occurs
at the beginning of exercise, whereas respiratory rate typically
increases more toward peak exercise.
CPET reveals an increased VE, at comparable levels of
eﬀort, in heart failure patients with respect to age-matched
normal individuals [36]. At a given work rate, heart failure
patients show a higher VE than normal subjects, the result of
an exaggerated respiratory rate response, and a truncated VT
response [5] (Figure 2).
Ventilatory response may be abnormal during exercise
despite normal breathing reserve as showed in diﬀerent
settings and in heart failure patients [12, 37, 38]. Lung
hyperinflation and expiratory flow limitation can cause
fatigue of the inspiratory muscles; therefore, it becomes clear
that breathing reserve is insuﬃcient for a comprehensive
and precise assessment of the contribution of the respiratory
system to physical exercise in physiologic and disease con-
ditions. Indeed, diminished respiratory muscle strength has
been demonstrated in heart failure patients. Mouth inspi-
ratory and expiratory pressures are reduced in heart failure
compared to normal subjects, and they seem to be correlated
with exercise capacity [39]. Moreover, inspiratory muscle
strength has independent prognostic value in heart failure.
The results of trials with inspiratory muscle training [40]
indicate that this intervention improves exercise capacity and
quality of life in heart failure. Some benefit from muscle
training may be accounted for by the attenuation of the
inspiratory muscle metaboreflex. Furthermore, inspiratory
muscle training results in improved cardiovascular responses
to exercise. These findings suggest that routine screening
for intercostal muscle weakness is advisable in patients with
heart failure and specific inspiratory muscle training and/or
aerobic training are of practical value in the management of
these patients.
More detailed information about ventilatory abnormali-
ties during exercise in heart failure is provided by analysis of
the spontaneous expiratory flow-volume loop relative to the
maximal forced curve. Expiratory flow limitation is reached
when the right upper corner of the flow-volume loop curve
is very close to the maximal flow volume curve registered at
rest. When this happens, subjects stop the eﬀort or proceed
through the exercise but the flow volume curve shifts to the
left, away from the functional residual capacity, in a region
where the cost of breathing increases. Johnson et al. [41]
and Agostoni et al. [12] showed that in heart failure, because
of lung stiﬀness, the spontaneous flow-volume loop reaches
the maximal flow-volume loop and the expiratory flow
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Figure 2: Tidal volume versus ventilation in patients with severe heart failure (peak VO2 < 12 mL/min/kg, black circles), moderate to severe
heart failure (peak VO2 12–16 mL/min/kg, black squares), moderate (peak VO2 > 16 mL/min/kg, empty circles), and normal subjects (empty
squares). From [5]. Reproduced with permission.
reserve is dramatically reduced, requiring an increase in end-
inspiratory lung volume. An increase in end-inspiratory lung
volume raises work of breathing and decreases inspiratory
endurance time [41]. In addition, after exercise in healthy
subjects, the maximal flow-volume loop is increased due a
bronchodilation induced by exercise; this is not the case in
heart failure [42]. Figure 3 describes an example of flow-
volume curves’ behavior during exercise in a normal subject
and in a heart failure patient. Moreover, Bussotti et al. [43]
showed that maximal flow-volume loops maneuver does not
interfere with the main functional parameters used for the
interpretation of CPET. Consequently, with a single CPET
both flow-volume curve and ventilation eﬃciency (VE/
VCO2 slope) can be evaluated.
3.1. Ventilation versus VCO2. In normal subjects the relation
of VE versus VCO2 is characterized during CPET progressive
work load increase by three linear relationships. The three
slopes are progressively steeped. This is due to the change
in the functional parameters governing the VE versus VCO2
relationship and specifically VO2, VCO2, and pH [44].
Clinically the VE versus VCO2 slope is measured from the
first minute after the beginning of loaded pedaling to the
end of isocapnic period (Figure 4), albeit some authors [45]
suggest to measure the slope obtained considering the
entire exercise as a single linear relationship. Diﬀerently the
VE/VCO2 ratio declines at the beginning of exercise, reaches
a plateau, and increases in the last part of exercise, when
metabolic acidosis becomes unbuﬀered. In heart failure
exercise is characterized by hyperventilation, which is likely
due to several causes, including alteration of lung mechanics,
reduced lung diﬀusion, increased CO2 production due to
early lactic acidosis, increased VD, decreased ventilatory
eﬃciency, and overactive reflexes from metaboreceptors,
baroreceptors, and chemoreceptors. In other words, in heart
failure patients, besides abnormalities in the lung, either due
to mechanics or to gas exchange, also ventilatory control is
altered. The latter is likely a part of deranged cardiorespi-
ratory reflex control. Indeed, a direct link between exercise
hyperventilation and impaired reflexes which control heart
rate and blood pressure has been convincingly proposed
[46] providing the physiological base of the link between
hyperventilation and poor prognosis in heart failure. Ven-
tilatory eﬃciency is best defined by the relationship of the
amount of ventilation required to eliminate a given amount
of CO2. Eﬃciency of ventilation can be expressed as a slope
of the VE/VCO2 relationship or as VE/VCO2 ratio measured
either at the anaerobic threshold or as the lowest value
recorded during exercise. The modified alveolar equation
[44] concisely describes the determinants of the steepness
which VE rises with respect to VCO2:
VE
VCO2
= K
[PaCO2 × (1−VD/VT)] , (1)
where [K/PaCO2 × (1− VD/VT)] is the slope, K is constant
to adjust for standard temperature pressure dry and body
temperature pressure saturated and to convert fractional
concentrations to pressures, PaCO2 is partial pressure of CO2
in arterial blood, and VD/VT is the fraction of VT that goes
to VD. This equation is linear over a wide range of exercise.
Figure 4 describes a theoretical example of VE/VCO2 slope in
a normal subject and in a patient with heart failure. If PaCO2
is driven down by a high ventilatory drive from peripheral
chemoreceptors or by ergoreceptors in skeletal muscles, the
slope of the VE/VCO2 will increase as well as if VD/VT is
high. Little is known about chemosensitivity in heart failure.
It has been documented that central hypercapnic chemo-
sensitivity is enhanced in patients with heart failure with
central sleep apnea [47]. Chua et al. [48] demonstrated
that there is increased hypoxic and central hypercapnic
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Figure 3: Tidal flow-volume loops at rest (dashed lines) at 40% of maximal ventilation (thin solid lines), and at maximum exercise (thick
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Figure 4: VE/VCO2 slope in an heart failure patient (a) and an healthy control (b).
chemo-sensitivity in patients with heart failure, and that
its suppression with dihydrocodeine is associated with a
reduction of exercise ventilation, an improvement in exercise
tolerance, and a decrease in breathlessness [49]. Piepoli et al.
[50] showed that muscle reflex (ergoreflex) has an important
eﬀect on the ventilatory responses to exercise in heart failure
compared to control subjects, and that training may reduce
this exaggerated ergoreflex activity, thereby improving the
response to exercise. The increase in reflex sensitivity may
serve as a compensatory mechanism producing an increase in
ventilatory response during exercise and thereby preserving
blood gas homeostasis, also maintaining arterial oxygen
concentration. Studies analyzing the eﬀect of drugs inter-
fering with chemo-sensitivity are on-going, and no data are
available at present.
In normal subjects, VE/VCO2 relationship, for incre-
mental exercise, is normally linear up to the “respiratory
compensation point,” when ventilatory compensation begins
in response to metabolic (lactic) acidosis. Over the linear
phase of the VE/VCO2 relationship, below the respiratory
compensation point, the profile of VE/VCO2 closely reflects
that of VD/VT, providing information on ventilatory eﬃ-
ciency. In heart failure, hyperventilation is associated with
an increased VD/VT and VCO2 and a lower PaCO2 when
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compared to similar normal subjects at a similar percent of
VO2 peak [5]. Patients with heart failure often have a reduced
tidal volume at heavy exercise [5], which would increase the
VD/VT ratio; however, Buller and Poole-Wilson [51] showed
that the increased ventilatory response to exercise in patients
with heart failure is largely caused by mechanisms other
than increased ventilation of anatomical VD [51]. In heart
failure patients, in the absence of coexisting lung disease, this
pattern of a high VD/VT ratio with normal arterial blood
gases suggests that nonuniformity of ventilation/perfusion
(V/Q) ratios in the lung is more likely caused by increased
non-uniformity of perfusion than of ventilation [52]. A
totally diﬀerent behavior of the VE/VCO2 relationship is
likely when respiratory comorbidities, such as emphysema,
are present [53, 54].
The normal VE/VCO2 at the nadir is between 25 and 35.
Normal values for these ventilatory equivalents with an end-
tidal of CO2 (PetCO2) of approximately 40 mmHg suggest a
normal VD/VT and uniform matching of V/Q [44].
In recent years, the VE/VCO2 slope has gained notoriety
in the heart failure population as an outstanding prognostic
marker. Several studies report the VE/VCO2 slope to be
prognostically superior to peak VO2 to predict mortality [55–
60]. Arena et al. [55] built a classificatory system based on
exercise VE/VCO2 slope to stratify the risk of major cardio-
vascular events in heart failure. Corra` et al. [56] used VE/
VCO2 slope (with a cutoﬀ >34) for eﬃcient prognostic
stratification in patients with moderate to severe heart failure
(defined as VO2/kg peak 10–18 mL/kg/min). Ponikowski et
al. [60] showed that, even in heart failure patients with
normal exercise performance and peak VO2 >18 mL/kg/min,
abnormal exercise ventilation significantly discriminates
survival. Guazzi et al. [61] suggested that the VE/VCO2 slope
has a remarkable value for risk stratification even in patients
with diastolic heart failure.
Another way to assess ventilation during exercise is to
analyze the relationship between end-tidal CO2 pressure
(PetCO2) and VE during the isocapnic buﬀering period [44,
62]. At sea level, during isocapnic buﬀering period, there is a
straight relationship between CO2 set point and ventilation.
PetCO2, equivalent to PaCO2, during the isocapnic buﬀering
period, is around 40 mmHg in normal subjects, higher in
athletes [63] and lower in heart failure patients. Guazzi et al.
[64] suggested that a low peak PaCO2 (and consequently a
low peak PetCO2 and an elevated VD/VT) is a strong inde-
pendent predictor of mortality in stable heart failure, and
that a low peak PaCO2 is the most significant determinant
of the prognostic value of a steep VE/VCO2 slope. Another
ventilation-related index with a prognostic value in heart
failure is Oxygen Uptake Eﬃciency Slope (OUES). OUES is
derived from the relation between oxygen uptake (VO2 L/
min) and VE (L/min) during incremental exercise. OUES is
determined by the linear relation of VO2 (y-axis) versus the
logarithm of VE (x-axis) during exercise [65].
The following equation was used to determine the
relation between VO2 and VE:
VO2 = a log VE + b. (2)
The diﬀerential of this equation by VE yields is
dVO2
dVE
= a
(
1/ log 10
)
VE
, (3)
where a is the constant that represents the rate of increase in
VO2 in response to VE. We define the constant “a” as the
OUES. Baba et al. [65] emphasized the value of OUES as
a submaximal, eﬀort-independent, and objective parameter
to estimate cardiorespiratory functional reserve, and they
reported that OUES strongly correlates with VO2 max(r =
0.941).
Myers et al. [66], when defining a CPET score for
predicting outcomes in heart failure, considered OUES to
be a stronger predictor of risk than peak VO2. Davies et al.
[67] claimed OUES as a prognostic marker in heart failure
patients. Sun et al. [68] have recently described the Oxy-
gen Uptake Eﬃciency highest Plateau (OUEP, i.e., oxygen
uptake/ventilation = VO2/VE) as the best single predictor of
early death (six months), in a cohort of 508 patients with low
ejection fraction (>35%), with an Odds ratio for mortality
of 13. When OUEP is combined with periodic breathing, the
Odds ratio increases to 56.
3.2. Periodic Breathing. Periodic breathing is a ventilatory
pattern, which is present in some heart failure patients both
at rest and during exercise. Exercise-induced periodic breath-
ing has been defined by Kremser et al. [69] as the presence
of cyclic fluctuation of VE lasting longer than 66% of the
exercise, with an amplitude of more than 15% of the average
value at rest. It can be observed during the entire exercise
or it disappears after a few minutes. The origin of periodic
breathing is still unclear and several mechanisms have been
proposed, mainly grouped into ventilatory (instability in the
feedback ventilatory system) and hemodynamic (pulmonary
blood flow fluctuations). Agostoni et al. [70], showed that,
adding 250 and 500 mL of dead space, respectively, periodic
breathing disappears earlier during exercise and suggested
that low tidal volume and carbon dioxide apnea threshold are
important contributors to periodic breathing. Schmid et al.
[71] supposed that periodic breathing in heart failure might
potentiate the negative eﬀects of low cardiac output and high
ventilation on exercise performance, and they concluded that
the presence of periodic breathing negatively influences the
exercise performance of heart failure patients, likely because
of an increased cost of breathing. Indeed, periodic breathing
disappearance during exercise showed to be associated with
a more eﬃcient oxygen delivery in most cases. Regardless,
periodic breathing is associated with a worse prognosis [64,
72] in heart failure and reflects disease severity [73].
4. Therapeutic Interventions
Several reports showed that the respiratory system can
be one of the targets for proper heart failure treatment.
On this regard, several therapeutic interventions aﬀect the
ventilatory abnormalities both at rest and during exercise in
heart failure patients. Indeed, ACE-inhibition improves pul-
monary diﬀusion in heart failure [74]. ACE-inhibition could
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improve pulmonary hemodynamic, remove interstitial fluid
and pulmonary vasoconstriction, and improve DLCO. The
eﬀect of ACE-inhibitors is counteracted by aspirin, suggest-
ing that bradykinin metabolism has a role, and bradykinin
is likely to participate to abnormal alveolar capillary gas
diﬀusion regulation in heart failure. Most importantly the
studies on ACE-inhibitors, with and without aspirin, showed
a direct eﬀect of these drugs on lung gas diﬀusion, in the
absence of a hemodynamic eﬀect [74]. Agostoni et al. [75]
showed that spironolactone improves gas diﬀusion through
the lungs in stable heart failure patients with impaired
DLCO, possibly through a reduction of pulmonary fibrosis.
Also Beta-blockers aﬀect DLCO diﬀusion. Beta-receptors
in the lung are located on the alveoli, mainly Beta2-receptors,
and on the airways (mainly Beta1-receptor). Carvedilol
reduces DLCO, due to a reduction of membrane diﬀusion
[62], while Bisoprolol does not modify DLCO [76]. Car-
vedilol and Bisoprolol have a diﬀerent pharmacological
action, blocking both Beta1- and Beta2-receptors (Car-
vedilol) or selectively Beta1-receptor (Bisoprolol). The phar-
macological action of Beta-blockers can explain the dif-
ferent actions on DLCO diﬀusion. Carvedilol improves
clinical conditions, without aﬀecting exercise performance.
Carvedilol, but not Bisoprolol, reduces hyperventilation
through exercise [77], as shown by a lower VE/VCO2 slope,
consequent to an increase in the arterial CO2 set point
[62, 78]. The improvement of the clinical conditions of heart
failure patients treated with Carvedilol could be associated
with reduction of the inappropriately elevated ventilation
levels observed during exercise and consequently dyspnea.
A direct eﬀect of Carvedilol on chemoreceptors activity
has been recently suggested [79]. This reduction of hyperven-
tilation during exercise is present both in normoxia (equiv-
alent to sea level) and in hypoxia (equivalent to 2,000 m
altitude). The reduction of hyperventilation by Carvedilol
has a negative influence on arterial PO2 during exercise at
a simulated altitude of 2,000 m [78].
In conclusion, lung abnormalities have a major role in
heart failure syndrome. Indeed, lung abnormalities influence
the clinical setting being dyspnea, a frequently reported heart
failure symptom, aﬀecting exercise performance, providing
a tool to grade heart failure severity and to predict its
prognosis, and finally being the target of therapy with several
drugs commonly used in heart failure.
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